Australasian Myeloma Research Consortium

The Australasian Myeloma Research Consortium (AMaRC) is a prominent academic research organization dedicated to the design and execution of investigator-initiated clinical trials for multiple myeloma and related plasma cell disorders. Operating across Australia and New Zealand, AMaRC serves as a critical bridge between laboratory innovation and clinical practice, collaborating with global pharmaceutical partners to provide patients with access to novel therapeutic agents. The consortium manages a diverse portfolio of trials, ranging from early-phase dose-escalation studies to large-scale Phase 3 comparative evaluations. By leveraging a robust network of specialized clinical sites and expert hematologists, AMaRC aims to optimize treatment strategies and improve long-term survival outcomes for patients living with myeloma.